- Home
- EU vs PHAR Comparison
EU vs PHAR Comparison
Compare EU & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- PHAR
- Stock Information
- Founded
- EU 2009
- PHAR 1988
- Country
- EU United States
- PHAR Netherlands
- Employees
- EU N/A
- PHAR N/A
- Industry
- EU Other Metals and Minerals
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- PHAR Health Care
- Exchange
- EU Nasdaq
- PHAR Nasdaq
- Market Cap
- EU N/A
- PHAR 731.1M
- IPO Year
- EU N/A
- PHAR N/A
- Fundamental
- Price
- EU $2.68
- PHAR $10.00
- Analyst Decision
- EU Strong Buy
- PHAR Strong Buy
- Analyst Count
- EU 1
- PHAR 3
- Target Price
- EU $2.75
- PHAR $30.00
- AVG Volume (30 Days)
- EU 3.5M
- PHAR 3.6K
- Earning Date
- EU 08-13-2025
- PHAR 07-31-2025
- Dividend Yield
- EU N/A
- PHAR N/A
- EPS Growth
- EU N/A
- PHAR N/A
- EPS
- EU N/A
- PHAR N/A
- Revenue
- EU $46,179,000.00
- PHAR $320,708,000.00
- Revenue This Year
- EU $27.46
- PHAR $13.31
- Revenue Next Year
- EU $140.12
- PHAR $7.68
- P/E Ratio
- EU N/A
- PHAR N/A
- Revenue Growth
- EU N/A
- PHAR 24.13
- 52 Week Low
- EU $1.01
- PHAR $6.65
- 52 Week High
- EU $4.44
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- EU 58.46
- PHAR 43.61
- Support Level
- EU $2.52
- PHAR $9.99
- Resistance Level
- EU $2.93
- PHAR $10.59
- Average True Range (ATR)
- EU 0.20
- PHAR 0.35
- MACD
- EU -0.03
- PHAR -0.14
- Stochastic Oscillator
- EU 60.00
- PHAR 7.45
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.